Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106885

Increase in Fibrinogen and Fibrin-Related Antigen in Human Serum Due to In Vitro Lysis of Fibrin by Thrombin

Clarence Merskey, Alan J. Johnson, and Parviz Lalezari

Department of Medicine and Unit for Research in Aging, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10461

Department of Medicine, New York University Medical Center, New York 10016

Montefiore Hospital and Medical Center, Bronx, New York 10467

Find articles by Merskey, C. in: PubMed | Google Scholar

Department of Medicine and Unit for Research in Aging, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10461

Department of Medicine, New York University Medical Center, New York 10016

Montefiore Hospital and Medical Center, Bronx, New York 10467

Find articles by Johnson, A. in: PubMed | Google Scholar

Department of Medicine and Unit for Research in Aging, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10461

Department of Medicine, New York University Medical Center, New York 10016

Montefiore Hospital and Medical Center, Bronx, New York 10467

Find articles by Lalezari, P. in: PubMed | Google Scholar

Published April 1, 1972 - More info

Published in Volume 51, Issue 4 on April 1, 1972
J Clin Invest. 1972;51(4):903–911. https://doi.org/10.1172/JCI106885.
© 1972 The American Society for Clinical Investigation
Published April 1, 1972 - Version history
View PDF
Abstract

In vitro lysis of fibrin, as indicated by increased fibrinogen-fibrin-related antigen (FR-antigen) in serum is usually seen when whole blood, or plasma, or highly purified fibrinogen prepared by several different procedures is clotted and kept at temperatures above 0°C. This increase is both time and temperature dependent, occurs despite the addition of various plasmin and cathepsin inhibitors, and is probably caused by thrombin evolved during clotting and/or added in vitro. In these experiments, the FR-antigen was measured by a sensitive, reproducible hemagglutination inhibition immunoassay adapted to the AutoAnalyzer. Serum from whole blood contained more than serum from plasma, and fibrin rather than fibrinogen proved to be essential for the in vitro lysis. The phenomenon was also caused by Arvin or Reptilase, suggesting that splitting of one or more arginine or lysine bonds in fibrin may be at least partially responsible. To obtain minimal levels of FR-antigen (< 0.5 μg/ml), plasma is clotted for 4 hr at 0°C with 1.0-5.0 U/ml thrombin, CaCl2 (0.0125 mole/liter), and epsilon aminocaproic acid (0.05 mole/liter). Slightly higher levels, probably adequate for clinical diagnosis, are obtained by 10-30 min clotting at room temperature. Since endogenous and/or exogenous thrombin is essential for the collection of serum FR-antigen, all the FR-antigen found in normal serum probably results from an irreducible amount of in vitro lysis rather than from continuous intravascular clotting and fibrinolysis.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 903
page 903
icon of scanned page 904
page 904
icon of scanned page 905
page 905
icon of scanned page 906
page 906
icon of scanned page 907
page 907
icon of scanned page 908
page 908
icon of scanned page 909
page 909
icon of scanned page 910
page 910
icon of scanned page 911
page 911
Version history
  • Version 1 (April 1, 1972): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts